Setting Standards Empowering Research Building Shareholder Value First Quarter 2025 Financial Results May 6th 2025 Legal Information Forward-looking statements This presentation contains forward-looking statements that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact (including statements containing the words "believes," "plans," "anticip ...

Tempus AI, Inc. Investor Presentation Q1 2025 May 6, 2025 Disclaimer This presentation contains forward-looking statements that reflect Tempus AI, Inc.'s (the "Company" or "Tempus") current expectations and projections with respect to, among other things, its financial condition, results of operations, plans, objectives, future performance and business. Forward-looking statements include all statements that are not historical facts. Such forward-looking statements are subject to various risks and uncertaint ...

Corporate Presentation Using Proven, Innovative Adjuvant Technology to Help Protect the World Against Infectious Diseases Advance Differentiated Vaccine Pipeline Identify Strategic Opportunities to Accelerate Growth © Copyright DYNAVAX 2025 3 | May 2025 Nasdaq: DVAX Forward-Looking Statements Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statement ...

COMBINING TO CURE ® Arcus is at the forefront of designing combination therapies, with best-in-class potential, in the relentless pursuit of cures for cancer. May 6, 2025 CORPORATE PRESENTATION Notice of Trademark: The Arcus name and logo are the property of Arcus. All other trademarks used herein are the property of their respective owners and are used for reference purposes only. Such use should not be construed as an endorsement of Arcus. Forward-Looking Statements/Safe Harbor Forward Looking Statements ...

Q1 2025 Investor Presentation 05.06.2025 This presentation includes certain "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Other than statements of historical facts, all statements contained in this presentation and accompanying oral commentary, including, but not limited to, statements about Klaviyo's outlook for the second quarter of fiscal year 2025 and the full fiscal year ending December 31, 2025, and Kl ...

Halozyme Therapeutics, Inc. First Quarter Financial & Operating Results NASDAQ: HALO May 6, 2025 1 Forward-Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future financial performance and growth rates (including the Company's 2025 financial guidance and longer term financial outlook through 2028 and the assumptions used in deriving such guidan ...

Revenue +6% QoQ +23% $274M YoY Q1 2025 -7% QoQ +11% YoY Origination vol. market share (1) 1.3% Market share PTNI -$46M Q1 2025 +45% QoQ +46% YoY PTNI +7% QoQ +29% 1.9% YoY Unit share Volume share Conv / Gov Delta: -5 / +1% QoQ -15 / +5% YoY Product Mix 1Q '25 FINANCIAL HIGHLIGHTS UPB & servicing revenue +1% QoQ -18% YoY UPB Expenses by Category $223 $265 $315 $257 $274 $0 $100 $200 $300 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Revenue ($M) $142 $114 $115 $116 $117 $70 $100 $130 $100 $140 Q1 '24 Q2 '24 Q3 '24 Q4 ' ...

CONNECT WITH NATURE Q1 2025 Earnings Presentation May 6, 2025 S A F E H A R B O R S T A T E M E N T S Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements regarding the Company's future business expectations, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans, strategies and financial results, ...

Q3 FY25 Conference Call May 6, 2025 Forward Looking Statements and Financial Presentation This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These include statements regarding: our belief and expectations with respect to our markets, including the cloud end market and the broader networking market, customers and industry, any anticipation or guidance as to demand for our products and te ...

Q1 2025 earnings May 6, 2025 Forward looking statements This presentation contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including but not limited to, information or predictions concerning our future financial performance, including our financial outlook for Q2 2025 and the full fiscal year 2025 under the heading "Outlook" and management's estimates under the heading "Marke ...